Imodium

Loperamide Hydrochloride, the active ingredient in Imodium, is an antidiarrheal presented as an oral dosage form for oral use. It reduces the frequency and urgency of watery stools in adults and children over two years of age with acute or chronic diarrhea. It is available over the counter in many European countries.

GNH USA supplies Imodium as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Imodium (loperamide) acts on the gastrointestinal tract to control excessive bowel movements associated with diarrheal conditions.

Acute diarrhea: reduces stool frequency and improves consistency in short‑term episodes. Chronic diarrhea: helps manage persistent loose stools in conditions such as irritable bowel syndrome with diarrhea. Travel‑related diarrhea: alleviates symptoms caused by infectious agents during travel.

Loperamide may cause a range of adverse reactions, most of which are mild and dose‑related.

Common Side Effects: - Constipation: hard stools or difficulty passing stool. - Abdominal cramps: mild to moderate discomfort in the abdomen. - Nausea: feeling of sickness or urge to vomit. - Dizziness or drowsiness: transient light‑headedness or sleepiness.

Serious or Rare Side Effects: - Severe constipation leading to ileus or bowel obstruction. - Toxic megacolon: rapid colon dilation that can be life‑threatening. - Allergic reactions: rash, itching, swelling, or anaphylaxis.

Before using Imodium, consider the following safety measures to minimize risks.

Age restriction: avoid use in children younger than two years. Infectious diarrhea: do not use when diarrhea is caused by bacterial toxins or parasites without medical advice. Hepatic impairment: use with caution in patients with liver disease, as drug clearance may be reduced. Concomitant medications: avoid combining with strong CYP3A4 or CYP2C8 inhibitors that can increase systemic exposure. Monitor for constipation: discontinue if severe constipation or abdominal distension occurs. Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture.

Loperamide can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise loperamide levels and risk cardiac toxicity. - Strong CYP2C8 inhibitors (e.g., gemfibrozil): increase systemic exposure, heightening adverse effects. - Other opioid antidiarrheals: additive effect on gut motility leading to severe constipation.

Moderate Interactions (Monitor Closely): - QT‑prolonging agents (e.g., macrolide antibiotics, antiarrhythmics): may enhance risk of cardiac arrhythmias. - Anticholinergic drugs: combined effect may worsen constipation. - Certain antidepressants (e.g., sertraline): monitor for increased central nervous system side effects.